SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-110139
Filing Date
2024-04-24
Accepted
2024-04-24 16:20:03
Documents
14
Period of Report
2024-04-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d820728d8k.htm   iXBRL 8-K 23555
2 EX-99.1 d820728dex991.htm EX-99.1 6825
  Complete submission text file 0001193125-24-110139.txt   152140

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20240422.xsd EX-101.SCH 2896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20240422_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20240422_pre.xml EX-101.PRE 10843
17 EXTRACTED XBRL INSTANCE DOCUMENT d820728d8k_htm.xml XML 3481
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 24870860
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)